Krina Patel

Dr. Krina K. Patel is an Associate Professor, Multiple Myeloma Section Chief, and Director of Myeloma Clinical Research in the Department of Lymphoma and Myeloma within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. She received her medical degree from the University of Texas Southwestern Medical Center and completed her hematology-oncology fellowship at MD Anderson, where she served as Chief Fellow.
Dr. Patel has held multiple leadership roles at MD Anderson, including Center Medical Director, Service Line Leader, and Associate Program Director for the Hematology-Oncology Fellowship Program. She is a nationally recognized clinical investigator and serves as national principal investigator for multiple clinical trials in multiple myeloma, including studies of novel cellular therapies.
Her research focuses on improving outcomes for patients with multiple myeloma and other plasma cell disorders, with an emphasis on CAR T-cell therapy and the integration of immunotherapy and chemotherapy across disease settings. Her additional interests include POEMS syndrome and plasmablastic lymphoma.
She has led numerous clinical trials in immunotherapy and currently directs several CAR T-cell studies. Dr. Patel is also a dedicated mentor to fellows, residents, and junior faculty.
She is a member of ASH, ASCO, AACR, ASTCT, the International Myeloma Society, and the Multiple Myeloma Research Foundation (MMRF), and has published extensively in leading journals including NEJM, JCO, Blood, and The Lancet.

Dr Mikhael is a Professor in the Clinical Genomics and Therapeutics Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Director of Myeloma research at the HonorHealth Research Institute in Scottsdale, Arizona. Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom’s macroglobulinemia. He is the PI of many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations.

Dr. Mikhael recently served as the Chief Medical Officer of the International Myeloma Foundation (IMF) from 2018 to 2026 – he now serves as Medical Advisor to the IMF to provide guidance and strategic input in areas such as patient education, health disparities, collaboration with partners, international research, and publications.

Dr Mikhael has published over 200 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr. Mikhael is deeply committed to health disparities in myeloma and is the chair of the Diversity, Equity and Inclusion Council at TGen. Dr. Mikhael is heavily involved in training future researchers and mentors junior faculty worldwide. Dr. Mikhael is an active member of the International Myeloma Working Group (IMWG) and recently led the ASCO guidelines in myeloma. Dr. Mikhael also serves as the Treasurer on the executive of the American Society of Hematology.

Prashant Kapoor, MD, FACP, is a Consultant, Professor of Medicine and Professor of Oncology at Mayo Clinic. He is the Chair of the Myeloma, Amyloidosis and Dysproteinemia Group at Mayo Clinic, Rochester.
He was awarded the Kurtz Myeloma Research Fellowship at Mayo Clinic in 2008 following which he commenced his clinical fellowship training in Hematology and Oncology at Mayo Clinic. Upon completion of his training in 2012, he was invited to serve as faculty in the Division of Hematology, Mayo Clinic.

He is a recipient of several awards, including the American Society of Clinical Oncology (ASCO) Merit Award, Department of Medicine (DOM) Career Development Award, Research Innovation Award, Transplant Center Scholar Award and the Department of Medicine Faculty Scholar Award.

His research is focused in evaluating novel agents in plasma cell disorders. He is a PI of several investigator-initiated and industry-sponsored clinical trials. He has served on Mayo Clinic Institutional Review Board, and is currently a member of Mayo Clinic Data Safety Monitoring Committee.

He is a passionate educator and has presented his work at national and international forums. He has served on the Editorial Board of the ASH Daily News and is the Myeloma Section Editor of Current Hematologic Malignancy Reports and Co-Site Editor for Myeloma Section of JNCCN 360. He has over 400 publications in prestigious journals, including The Lancet, JAMA Oncology, JCO, The Lancet Oncology and Blood.

He is a fellow at the ACP, and an active member of the IMWG, ASH, ASCO and the IMS.

Dr. Krina K. Patel is an Associate Professor, Multiple Myeloma Section Chief, and Director of Myeloma Clinical Research in the Department of Lymphoma and Myeloma within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. She received her medical degree from the University of Texas Southwestern Medical Center and completed her hematology-oncology fellowship at MD Anderson, where she served as Chief Fellow.
Dr. Patel has held multiple leadership roles at MD Anderson, including Center Medical Director, Service Line Leader, and Associate Program Director for the Hematology-Oncology Fellowship Program. She is a nationally recognized clinical investigator and serves as national principal investigator for multiple clinical trials in multiple myeloma, including studies of novel cellular therapies.
Her research focuses on improving outcomes for patients with multiple myeloma and other plasma cell disorders, with an emphasis on CAR T-cell therapy and the integration of immunotherapy and chemotherapy across disease settings. Her additional interests include POEMS syndrome and plasmablastic lymphoma.
She has led numerous clinical trials in immunotherapy and currently directs several CAR T-cell studies. Dr. Patel is also a dedicated mentor to fellows, residents, and junior faculty.
She is a member of ASH, ASCO, AACR, ASTCT, the International Myeloma Society, and the Multiple Myeloma Research Foundation (MMRF), and has published extensively in leading journals including NEJM, JCO, Blood, and The Lancet.

Dr Mikhael is a Professor in the Clinical Genomics and Therapeutics Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Director of Myeloma research at the HonorHealth Research Institute in Scottsdale, Arizona. Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom’s macroglobulinemia. He is the PI of many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations.

Dr. Mikhael recently served as the Chief Medical Officer of the International Myeloma Foundation (IMF) from 2018 to 2026 – he now serves as Medical Advisor to the IMF to provide guidance and strategic input in areas such as patient education, health disparities, collaboration with partners, international research, and publications.

Dr Mikhael has published over 200 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr. Mikhael is deeply committed to health disparities in myeloma and is the chair of the Diversity, Equity and Inclusion Council at TGen. Dr. Mikhael is heavily involved in training future researchers and mentors junior faculty worldwide. Dr. Mikhael is an active member of the International Myeloma Working Group (IMWG) and recently led the ASCO guidelines in myeloma. Dr. Mikhael also serves as the Treasurer on the executive of the American Society of Hematology.

Samer Al Hadidi, M.D., M.S., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in hematology and oncology, with an emphasis on plasma cell disorders, including multiple myeloma and light chain amyloidosis, and cellular therapies, including CAR T-cell therapy and hematopoietic stem cell transplantation.

Dr. Al Hadidi earned his medical degree at the University of Jordan School of Medicine. He completed a residency in internal medicine at Hurley Medical Center/Michigan State University. He received advanced training through a hematology and oncology fellowship at Baylor College of Medicine in Houston. He also holds a master’s degree in clinical research and statistical analysis from the University of Michigan in Ann Arbor.

Dr. Al Hadidi is the Clinical Director of the Amyloidosis Program at UT Southwestern. He also serves as Leader of the Fellows’ Plasma Cell Disorders Clinic. He is nationally recognized as an expert in treating multiple myeloma and utilizing cellular therapies for plasma cell disorders.Dr. Al Hadidi serves on the Hematology Specialty Board of the American Board of Internal Medicine, helping to oversee certification standards, specialty assessment, and governance policies for hematology.

Dr. Al Hadidi has delivered national and international presentations and published more than 140 peer-reviewed academic articles related to his areas of expertise.

Dr Kaufman is a Professor in the Department of Hematology and Medical Oncology at Emory University. He is a member of the Winship Cancer Institute in the Drug Development and Therapeutics Program. He leads the multidisciplinary Amyloidosis program at Emory.

He is an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and other plasma cell disorders. His research focus is on the development of optimal treatment regimens and new drug development for patients with plasma cell disorders. His work has been published in journals such as NEJM, Journal of Clinical Oncology, Lancet Oncology, Lancet Haematology, Science Signaling, Blood, Leukemia and Blood Cancer Journal. He is a member of the International Myeloma Working Group as well as the International Myeloma Society.

Shaji K. Kumar, MD, is a Consultant in the Division of Hematology and the Mark and Judy Mullins Professor of Hematological Malignancies at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Myeloma, Amyloidosis, and Dysproteinemia Disease Group at the Mayo Clinic, as well as Research Chair for the Division of Hematology.

Dr. Kumar received his medical degree from the All India Institute of Medical Sciences, New Delhi, India. His postdoctoral training included a residency in Internal Medicine at the same institute, followed by a residency in Internal Medicine and a fellowship in hematology/oncology at the Mayo Clinic Graduate School of Medicine in Rochester, Minnesota. He then completed a Mayo Foundation Fellowship at the Dana-Farber Cancer Institute in Boston.

Dr. Kumar’s research centers on developing new drugs and drug combinations for treating myeloma. He is the Principal Investigator of multiple phase 1, 2, and 3 clinical trials. Additionally, he studies the mechanisms behind disease progression from precursor conditions and risk stratification of plasma cell disorders. His laboratory aims to understand the role of the bone marrow microenvironment in the development and progression of myeloma.

Dr. Kumar serves as Chair of the NCCN Multiple Myeloma Guidelines Panel. He is the President of the International Society of Amyloidosis and the Vice President of the International Myeloma Society. He is the current Editor in Chief of The Hematologist, the American Society of Hematology’s official member newsletter.

Dr. Krina K. Patel is an Associate Professor, Multiple Myeloma Section Chief, and Director of Myeloma Clinical Research in the Department of Lymphoma and Myeloma within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. She received her medical degree from the University of Texas Southwestern Medical Center and completed her hematology-oncology fellowship at MD Anderson, where she served as Chief Fellow.
Dr. Patel has held multiple leadership roles at MD Anderson, including Center Medical Director, Service Line Leader, and Associate Program Director for the Hematology-Oncology Fellowship Program. She is a nationally recognized clinical investigator and serves as national principal investigator for multiple clinical trials in multiple myeloma, including studies of novel cellular therapies.
Her research focuses on improving outcomes for patients with multiple myeloma and other plasma cell disorders, with an emphasis on CAR T-cell therapy and the integration of immunotherapy and chemotherapy across disease settings. Her additional interests include POEMS syndrome and plasmablastic lymphoma.
She has led numerous clinical trials in immunotherapy and currently directs several CAR T-cell studies. Dr. Patel is also a dedicated mentor to fellows, residents, and junior faculty.
She is a member of ASH, ASCO, AACR, ASTCT, the International Myeloma Society, and the Multiple Myeloma Research Foundation (MMRF), and has published extensively in leading journals including NEJM, JCO, Blood, and The Lancet.

Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He serves as the Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center and holds a faculty position as Professor of Clinical Medicine at Weill Cornell Medical College, Cornell University. Dr. Usmani is board-certified in internal medicine, medical oncology, and hematology. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the ALLIANCE Myeloma Committee (Chair), the American Society of Hematology (ASH), the American Society of Clinical Oncology, International Myeloma Society (Board Member), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research, the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research, and the LLS CDP Achievement Award. Dr. Usmani has authored/co-authored more than 370 peer-reviewed research manuscripts (NEJM, Lancet, JCO, Cancer Cell, Blood, Leukemia, etc.). Active in clinical and translational research, Dr. Usmani has research interests focused on plasma cell disorders—in particular, high-risk multiple myeloma.

Dr. Krina K. Patel is an Associate Professor, Multiple Myeloma Section Chief, and Director of Myeloma Clinical Research in the Department of Lymphoma and Myeloma within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. She received her medical degree from the University of Texas Southwestern Medical Center and completed her hematology-oncology fellowship at MD Anderson, where she served as Chief Fellow.
Dr. Patel has held multiple leadership roles at MD Anderson, including Center Medical Director, Service Line Leader, and Associate Program Director for the Hematology-Oncology Fellowship Program. She is a nationally recognized clinical investigator and serves as national principal investigator for multiple clinical trials in multiple myeloma, including studies of novel cellular therapies.
Her research focuses on improving outcomes for patients with multiple myeloma and other plasma cell disorders, with an emphasis on CAR T-cell therapy and the integration of immunotherapy and chemotherapy across disease settings. Her additional interests include POEMS syndrome and plasmablastic lymphoma.
She has led numerous clinical trials in immunotherapy and currently directs several CAR T-cell studies. Dr. Patel is also a dedicated mentor to fellows, residents, and junior faculty.
She is a member of ASH, ASCO, AACR, ASTCT, the International Myeloma Society, and the Multiple Myeloma Research Foundation (MMRF), and has published extensively in leading journals including NEJM, JCO, Blood, and The Lancet.

Dr Mikhael is a Professor in the Clinical Genomics and Therapeutics Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Director of Myeloma research at the HonorHealth Research Institute in Scottsdale, Arizona. Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom’s macroglobulinemia. He is the PI of many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations.

Dr. Mikhael recently served as the Chief Medical Officer of the International Myeloma Foundation (IMF) from 2018 to 2026 – he now serves as Medical Advisor to the IMF to provide guidance and strategic input in areas such as patient education, health disparities, collaboration with partners, international research, and publications.

Dr Mikhael has published over 200 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr. Mikhael is deeply committed to health disparities in myeloma and is the chair of the Diversity, Equity and Inclusion Council at TGen. Dr. Mikhael is heavily involved in training future researchers and mentors junior faculty worldwide. Dr. Mikhael is an active member of the International Myeloma Working Group (IMWG) and recently led the ASCO guidelines in myeloma. Dr. Mikhael also serves as the Treasurer on the executive of the American Society of Hematology.

Prashant Kapoor, MD, FACP, is a Consultant, Professor of Medicine and Professor of Oncology at Mayo Clinic. He is the Chair of the Myeloma, Amyloidosis and Dysproteinemia Group at Mayo Clinic, Rochester.
He was awarded the Kurtz Myeloma Research Fellowship at Mayo Clinic in 2008 following which he commenced his clinical fellowship training in Hematology and Oncology at Mayo Clinic. Upon completion of his training in 2012, he was invited to serve as faculty in the Division of Hematology, Mayo Clinic.

He is a recipient of several awards, including the American Society of Clinical Oncology (ASCO) Merit Award, Department of Medicine (DOM) Career Development Award, Research Innovation Award, Transplant Center Scholar Award and the Department of Medicine Faculty Scholar Award.

His research is focused in evaluating novel agents in plasma cell disorders. He is a PI of several investigator-initiated and industry-sponsored clinical trials. He has served on Mayo Clinic Institutional Review Board, and is currently a member of Mayo Clinic Data Safety Monitoring Committee.

He is a passionate educator and has presented his work at national and international forums. He has served on the Editorial Board of the ASH Daily News and is the Myeloma Section Editor of Current Hematologic Malignancy Reports and Co-Site Editor for Myeloma Section of JNCCN 360. He has over 400 publications in prestigious journals, including The Lancet, JAMA Oncology, JCO, The Lancet Oncology and Blood.

He is a fellow at the ACP, and an active member of the IMWG, ASH, ASCO and the IMS.

Dr. Krina K. Patel is an Associate Professor, Multiple Myeloma Section Chief, and Director of Myeloma Clinical Research in the Department of Lymphoma and Myeloma within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. She received her medical degree from the University of Texas Southwestern Medical Center and completed her hematology-oncology fellowship at MD Anderson, where she served as Chief Fellow.
Dr. Patel has held multiple leadership roles at MD Anderson, including Center Medical Director, Service Line Leader, and Associate Program Director for the Hematology-Oncology Fellowship Program. She is a nationally recognized clinical investigator and serves as national principal investigator for multiple clinical trials in multiple myeloma, including studies of novel cellular therapies.
Her research focuses on improving outcomes for patients with multiple myeloma and other plasma cell disorders, with an emphasis on CAR T-cell therapy and the integration of immunotherapy and chemotherapy across disease settings. Her additional interests include POEMS syndrome and plasmablastic lymphoma.
She has led numerous clinical trials in immunotherapy and currently directs several CAR T-cell studies. Dr. Patel is also a dedicated mentor to fellows, residents, and junior faculty.
She is a member of ASH, ASCO, AACR, ASTCT, the International Myeloma Society, and the Multiple Myeloma Research Foundation (MMRF), and has published extensively in leading journals including NEJM, JCO, Blood, and The Lancet.

Shaji K. Kumar, MD, is a Consultant in the Division of Hematology and the Mark and Judy Mullins Professor of Hematological Malignancies at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Myeloma, Amyloidosis, and Dysproteinemia Disease Group at the Mayo Clinic, as well as Research Chair for the Division of Hematology.

Dr. Kumar received his medical degree from the All India Institute of Medical Sciences, New Delhi, India. His postdoctoral training included a residency in Internal Medicine at the same institute, followed by a residency in Internal Medicine and a fellowship in hematology/oncology at the Mayo Clinic Graduate School of Medicine in Rochester, Minnesota. He then completed a Mayo Foundation Fellowship at the Dana-Farber Cancer Institute in Boston.

Dr. Kumar’s research centers on developing new drugs and drug combinations for treating myeloma. He is the Principal Investigator of multiple phase 1, 2, and 3 clinical trials. Additionally, he studies the mechanisms behind disease progression from precursor conditions and risk stratification of plasma cell disorders. His laboratory aims to understand the role of the bone marrow microenvironment in the development and progression of myeloma.

Dr. Kumar serves as Chair of the NCCN Multiple Myeloma Guidelines Panel. He is the President of the International Society of Amyloidosis and the Vice President of the International Myeloma Society. He is the current Editor in Chief of The Hematologist, the American Society of Hematology’s official member newsletter.

Samer Al Hadidi, M.D., M.S., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in hematology and oncology, with an emphasis on plasma cell disorders, including multiple myeloma and light chain amyloidosis, and cellular therapies, including CAR T-cell therapy and hematopoietic stem cell transplantation.

Dr. Al Hadidi earned his medical degree at the University of Jordan School of Medicine. He completed a residency in internal medicine at Hurley Medical Center/Michigan State University. He received advanced training through a hematology and oncology fellowship at Baylor College of Medicine in Houston. He also holds a master’s degree in clinical research and statistical analysis from the University of Michigan in Ann Arbor.

Dr. Al Hadidi is the Clinical Director of the Amyloidosis Program at UT Southwestern. He also serves as Leader of the Fellows’ Plasma Cell Disorders Clinic. He is nationally recognized as an expert in treating multiple myeloma and utilizing cellular therapies for plasma cell disorders.Dr. Al Hadidi serves on the Hematology Specialty Board of the American Board of Internal Medicine, helping to oversee certification standards, specialty assessment, and governance policies for hematology.

Dr. Al Hadidi has delivered national and international presentations and published more than 140 peer-reviewed academic articles related to his areas of expertise.

Prashant Kapoor, MD, FACP, is a Consultant, Professor of Medicine and Professor of Oncology at Mayo Clinic. He is the Chair of the Myeloma, Amyloidosis and Dysproteinemia Group at Mayo Clinic, Rochester.
He was awarded the Kurtz Myeloma Research Fellowship at Mayo Clinic in 2008 following which he commenced his clinical fellowship training in Hematology and Oncology at Mayo Clinic. Upon completion of his training in 2012, he was invited to serve as faculty in the Division of Hematology, Mayo Clinic.

He is a recipient of several awards, including the American Society of Clinical Oncology (ASCO) Merit Award, Department of Medicine (DOM) Career Development Award, Research Innovation Award, Transplant Center Scholar Award and the Department of Medicine Faculty Scholar Award.

His research is focused in evaluating novel agents in plasma cell disorders. He is a PI of several investigator-initiated and industry-sponsored clinical trials. He has served on Mayo Clinic Institutional Review Board, and is currently a member of Mayo Clinic Data Safety Monitoring Committee.

He is a passionate educator and has presented his work at national and international forums. He has served on the Editorial Board of the ASH Daily News and is the Myeloma Section Editor of Current Hematologic Malignancy Reports and Co-Site Editor for Myeloma Section of JNCCN 360. He has over 400 publications in prestigious journals, including The Lancet, JAMA Oncology, JCO, The Lancet Oncology and Blood.

He is a fellow at the ACP, and an active member of the IMWG, ASH, ASCO and the IMS.

Dr Kaufman is a Professor in the Department of Hematology and Medical Oncology at Emory University. He is a member of the Winship Cancer Institute in the Drug Development and Therapeutics Program. He leads the multidisciplinary Amyloidosis program at Emory.

He is an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and other plasma cell disorders. His research focus is on the development of optimal treatment regimens and new drug development for patients with plasma cell disorders. His work has been published in journals such as NEJM, Journal of Clinical Oncology, Lancet Oncology, Lancet Haematology, Science Signaling, Blood, Leukemia and Blood Cancer Journal. He is a member of the International Myeloma Working Group as well as the International Myeloma Society.

Dr. Krina K. Patel is an Associate Professor, Multiple Myeloma Section Chief, and Director of Myeloma Clinical Research in the Department of Lymphoma and Myeloma within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. She received her medical degree from the University of Texas Southwestern Medical Center and completed her hematology-oncology fellowship at MD Anderson, where she served as Chief Fellow.
Dr. Patel has held multiple leadership roles at MD Anderson, including Center Medical Director, Service Line Leader, and Associate Program Director for the Hematology-Oncology Fellowship Program. She is a nationally recognized clinical investigator and serves as national principal investigator for multiple clinical trials in multiple myeloma, including studies of novel cellular therapies.
Her research focuses on improving outcomes for patients with multiple myeloma and other plasma cell disorders, with an emphasis on CAR T-cell therapy and the integration of immunotherapy and chemotherapy across disease settings. Her additional interests include POEMS syndrome and plasmablastic lymphoma.
She has led numerous clinical trials in immunotherapy and currently directs several CAR T-cell studies. Dr. Patel is also a dedicated mentor to fellows, residents, and junior faculty.
She is a member of ASH, ASCO, AACR, ASTCT, the International Myeloma Society, and the Multiple Myeloma Research Foundation (MMRF), and has published extensively in leading journals including NEJM, JCO, Blood, and The Lancet.